Please assess the completion status of the following clinical trial:

Trial Title: Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes \> 5 years complicated by at least one of the following situations despite intensive insulin management:~  * Reduced awareness of hypoglycemia at plasma glucose levels \< 54 mg/dL~ * Metabolic lability/instability characterized by two or more episodes of severe hypoglycemia or hospital visits for diabetic ketoacidosis over the last year~ * Progressive secondary complications of diabetes:~    * Retinopathy-three step progression using the ETDRS grading system or equivalent progression;~   * Nephropathy- microalbuminuria rise of 50 µg/min (72 mg/24h) over three months within the past two years despite using an ACE inhibitor;~   * Neuropathy-persistent gastroparesis, postural hypotension, neuropathic bowel or bladder, or severe peripheral neuropathy unresponsive to management~Exclusion Criteria:~* Co-existing cardiac disease:~  * Myocardial infarction within past six months~ * Angiographic evidence of non-correctable coronary artery disease~ * Ischemia on functional cardiac exam d. Heart failure \> NYHA II~* Active alcohol or substance abuse or cigarette smoking~* Psychiatric disorder: schizophrenia, bipolar disorder, or major depression that is unstable on medication~* Non-adherence to prescribed regimens~* Active infection including hepatitis C, hepatitis B, HIV~* TB by history, current infection, or under treatment for suspected TB~* History of malignancies except squamous or basal skin cancer~* Stroke within the past 6 months~* BMI \> 26 kg/m2 or body weight \> 70 kg at screening visit~* C-peptide response to glucagon stimulation, any C-peptide ≥ 0.3 ng/mL~* Inability to provide informed consent~* Age less than 18 or greater than 65 years~* Creatinine clearance \< 85 mL/min/1.73 m2 by 24-hour urine collection~* Serum creatinine \> 1.5 mg/dL~* Macroalbuminuria \> 300 mg/24h~* Baseline Hb \< 12 gm/dL in women, \< 13 gm/dL in men~* Baseline liver function tests outside normal range~* Untreated proliferative retinopathy~* Positive pregnancy test, intent for pregnancy, male's intent to procreate, unwilling to use effective contraception, breast-feeding~* Previous transplant or PRA reactivity \> 20%)~* Insulin requirement \> 0.7 IU/kg/day~* HbA1C \> 12%~* Hyperlipidemia~* Chronic use of steroids~* Use of coumadin or other anticoagulant (except aspirin) or PT INR \> 1.5~* Addison's disease~* Allergy to radiographic contrast material

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Islet Cell Transplant) (Type: ACTIVE_COMPARATOR): 1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
- Group 2 (Islet Cell Transplant plus) (Type: ACTIVE_COMPARATOR): 1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).